David A. Siegel Biogen Inc. Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q3 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Biogen Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 427,600 shares of BIIB stock, worth $66.7 Million. This represents 0.2% of its overall portfolio holdings.

Number of Shares

427,600

Previous 192,500 122.13%

Holding current value

$66.7 Million

Previous $44.6 Million 85.74%

% of portfolio

0.2%

Previous 0.1%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$189.07 - $236.8 $44.5 Million - $55.7 Million	235,100 Added 122.13%	427,600 $82.9 Million
Q2 2024 Aug 14, 2024	BUY	$190.52 - $236.72 $4.04 Million - $5.02 Million	21,200 Added 12.38%	192,500 $44.6 Million
Q1 2024 May 15, 2024	BUY	$212.02 - $267.71 $27.6 Million - $34.9 Million	130,200 Added 316.79%	171,300 $36.9 Million
Q4 2023 Feb 14, 2024	SELL	$222.59 - $267.94 $2.63 Million - $3.16 Million	-11,800 Reduced 22.31%	41,100 $10.6 Million
Q3 2023 Nov 14, 2023	SELL	$253.3 - $285.89 $26.4 Million - $29.8 Million	-104,300 Reduced 66.35%	52,900 $13.6 Million
Q2 2023 Aug 14, 2023	SELL	$275.25 - $318.06 $39.6 Million - $45.8 Million	-144,000 Reduced 47.81%	157,200 $44.8 Million
Q1 2023 May 15, 2023	SELL	$256.56 - $292.34 $129 Million - $147 Million	-503,100 Reduced 62.55%	301,200 $83.7 Million
Q4 2022 Feb 14, 2023	SELL	$252.44 - $306.72 $18.2 Million - $22.1 Million	-72,000 Reduced 8.22%	804,300 $223 Million
Q3 2022 Nov 14, 2022	SELL	$194.69 - $268.46 $23.2 Million - $32 Million	-119,300 Reduced 11.98%	876,300 $234 Million
Q3 2022 Nov 14, 2022	SELL	$194.69 - $268.46 $23.2 Million - $32 Million	-119,300 Reduced 11.98%	876,300 $234 Million
Q2 2022 Aug 15, 2022	SELL	$187.54 - $223.02 $19.2 Million - $22.9 Million	-102,500 Reduced 9.33%	995,600 $203 Million
Q1 2022 May 16, 2022	BUY	$193.77 - $244.14 $125 Million - $157 Million	642,900 Added 141.23%	1,098,100 $231 Million
Q4 2021 Feb 14, 2022	BUY	$223.92 - $287.77 $90.6 Million - $116 Million	404,500 Added 797.83%	455,200 $109 Million
Q3 2021 Nov 15, 2021	BUY	$282.99 - $369.05 $14.3 Million - $18.7 Million	50,700 New	50,700 $14.3 Million
Q4 2020 Feb 16, 2021	SELL	$236.26 - $355.63 $2.29 Million - $3.45 Million	-9,700 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$264.77 - $305.71 $12.2 Million - $14.1 Million	-46,200 Reduced 82.65%	9,700 $2.75 Million
Q2 2020 Aug 14, 2020	SELL	$258.66 - $342.55 $8.3 Million - $11 Million	-32,100 Reduced 36.48%	55,900 $15 Million
Q1 2020 May 15, 2020	SELL	$268.85 - $341.04 $30.9 Million - $39.3 Million	-115,100 Reduced 56.67%	88,000 $27.8 Million
Q4 2019 Feb 14, 2020	SELL	$220.06 - $304.07 $87.7 Million - $121 Million	-398,500 Reduced 66.24%	203,100 $60.3 Million
Q3 2019 Nov 14, 2019	BUY	$217.44 - $243.88 $6.31 Million - $7.07 Million	29,000 Added 5.06%	601,600 $140 Million
Q2 2019 Aug 14, 2019	BUY	$219.29 - $241.72 $111 Million - $122 Million	504,800 Added 744.54%	572,600 $134 Million
Q1 2019 May 15, 2019	SELL	$216.71 - $338.96 $21 Million - $32.9 Million	-97,000 Reduced 58.86%	67,800 $16 Million
Q4 2018 Feb 14, 2019	BUY	$278.5 - $352.75 $36.2 Million - $45.9 Million	130,000 Added 373.56%	164,800 $49.6 Million
Q3 2018 Nov 14, 2018	BUY	$293.51 - $383.83 $6.96 Million - $9.1 Million	23,700 Added 213.51%	34,800 $12.3 Million
Q2 2018 Aug 14, 2018	BUY	$257.52 - $306.91 $2.6 Million - $3.1 Million	10,100 Added 1010.0%	11,100 $3.22 Million
Q1 2018 May 15, 2018	BUY	$260.13 - $367.91 $260,130 - $367,910	1,000 New	1,000 $274,000

Others Institutions Holding BIIB

# of Institutions

1,036

Shares Held

126M

Call Options Held

1.13M

Put Options Held

1.43M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $22.5B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account